Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. more
Time Frame | QNCX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.6% | -3.39% | 0.2% |
1-Month Return | 5.14% | -1.92% | 2.72% |
3-Month Return | 143.71% | -10.54% | 7.31% |
6-Month Return | 159.15% | -4.47% | 10.44% |
1-Year Return | 68.04% | 4.06% | 27.53% |
3-Year Return | -84.88% | 0.94% | 30.88% |
5-Year Return | -95.64% | 36.67% | 89.21% |
10-Year Return | -94.41% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 188.00K | 332.00K | 344.00K | 175.00K | 322.00K | [{"date":"2019-12-31","value":54.65,"profit":true},{"date":"2020-12-31","value":96.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.87,"profit":true},{"date":"2023-12-31","value":93.6,"profit":true}] |
Gross Profit | (188.00K) | (332.00K) | (344.00K) | (175.00K) | (322.00K) | [{"date":"2019-12-31","value":-18800000,"profit":false},{"date":"2020-12-31","value":-33200000,"profit":false},{"date":"2021-12-31","value":-34400000,"profit":false},{"date":"2022-12-31","value":-17500000,"profit":false},{"date":"2023-12-31","value":-32200000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 39.17M | 78.89M | 90.32M | 51.19M | 34.62M | [{"date":"2019-12-31","value":43.37,"profit":true},{"date":"2020-12-31","value":87.35,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":56.68,"profit":true},{"date":"2023-12-31","value":38.33,"profit":true}] |
Operating Income | (39.17M) | (78.89M) | (90.32M) | (52.02M) | (34.62M) | [{"date":"2019-12-31","value":-3916800000,"profit":false},{"date":"2020-12-31","value":-7889300000,"profit":false},{"date":"2021-12-31","value":-9031800000,"profit":false},{"date":"2022-12-31","value":-5201500000,"profit":false},{"date":"2023-12-31","value":-3462000000,"profit":false}] |
Total Non-Operating Income/Expense | 4.38M | 4.09M | 993.00K | 1.14M | 6.04M | [{"date":"2019-12-31","value":72.47,"profit":true},{"date":"2020-12-31","value":67.7,"profit":true},{"date":"2021-12-31","value":16.45,"profit":true},{"date":"2022-12-31","value":18.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (36.98M) | (76.85M) | (89.94M) | (51.94M) | (31.58M) | [{"date":"2019-12-31","value":-3698000000,"profit":false},{"date":"2020-12-31","value":-7684900000,"profit":false},{"date":"2021-12-31","value":-8994500000,"profit":false},{"date":"2022-12-31","value":-5194400000,"profit":false},{"date":"2023-12-31","value":-3158200000,"profit":false}] |
Income Taxes | (188.00K) | 2.17M | (620.00K) | (284.00K) | (197.00K) | [{"date":"2019-12-31","value":-8.66,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-28.58,"profit":false},{"date":"2022-12-31","value":-13.09,"profit":false},{"date":"2023-12-31","value":-9.08,"profit":false}] |
Income After Taxes | (36.79M) | (79.02M) | (89.33M) | (51.66M) | (31.39M) | [{"date":"2019-12-31","value":-3679200000,"profit":false},{"date":"2020-12-31","value":-7901870300,"profit":false},{"date":"2021-12-31","value":-8932500000,"profit":false},{"date":"2022-12-31","value":-5166000000,"profit":false},{"date":"2023-12-31","value":-3138500000,"profit":false}] |
Income From Continuous Operations | (36.98M) | (76.85M) | (89.94M) | (51.66M) | (28.02M) | [{"date":"2019-12-31","value":-3698000000,"profit":false},{"date":"2020-12-31","value":-7684900000,"profit":false},{"date":"2021-12-31","value":-8994500000,"profit":false},{"date":"2022-12-31","value":-5166000000,"profit":false},{"date":"2023-12-31","value":-2802500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (36.79M) | (76.85M) | (89.33M) | (51.66M) | (31.39M) | [{"date":"2019-12-31","value":-3679200000,"profit":false},{"date":"2020-12-31","value":-7684900000,"profit":false},{"date":"2021-12-31","value":-8932500000,"profit":false},{"date":"2022-12-31","value":-5166000000,"profit":false},{"date":"2023-12-31","value":-3138500000,"profit":false}] |
EPS (Diluted) | (2.90) | (2.63) | (3.03) | (1.60) | (0.85) | [{"date":"2019-12-31","value":-290,"profit":false},{"date":"2020-12-31","value":-263,"profit":false},{"date":"2021-12-31","value":-303,"profit":false},{"date":"2022-12-31","value":-160,"profit":false},{"date":"2023-12-31","value":-84.61,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
QNCX | |
---|---|
Cash Ratio | 8.82 |
Current Ratio | 9.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
QNCX | |
---|---|
ROA (LTM) | -16.50% |
ROE (LTM) | -79.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
QNCX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.64 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.36 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
QNCX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.80 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.44 |
Quince Therapeutics, Inc. (QNCX) share price today is $1.935
Yes, Indians can buy shares of Quince Therapeutics, Inc. (QNCX) on Vested. To buy Quince Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QNCX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Quince Therapeutics, Inc. (QNCX) via the Vested app. You can start investing in Quince Therapeutics, Inc. (QNCX) with a minimum investment of $1.
You can invest in shares of Quince Therapeutics, Inc. (QNCX) via Vested in three simple steps:
The 52-week high price of Quince Therapeutics, Inc. (QNCX) is $2.45. The 52-week low price of Quince Therapeutics, Inc. (QNCX) is $0.51.
The price-to-earnings (P/E) ratio of Quince Therapeutics, Inc. (QNCX) is
The price-to-book (P/B) ratio of Quince Therapeutics, Inc. (QNCX) is 1.80
The dividend yield of Quince Therapeutics, Inc. (QNCX) is 0.00%
The market capitalization of Quince Therapeutics, Inc. (QNCX) is $71.84M
The stock symbol (or ticker) of Quince Therapeutics, Inc. is QNCX